Skip to main content

Table 2 Total combined score (TCS), daily symptom score (DSS), and daily medication score (DMS) in the Canadian subpopulation during the peak and entire ragweed pollen season (FAS population)

From: Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis

 

Peak ragweed pollen season

Entire ragweed pollen season

Scale

Ragweed SLIT-tablet

Placebo

Ragweed SLIT-tablet

Placebo

TCS, LS mean

2.32

3.91

2.36

3.73

 n

99

124

99

124

 Difference vs placebo (95% CI)

 − 1.59 (− 2.54, − 0.65)

 − 1.36 (− 2.21, − 0.51)

 Reduction vs placebo, % (95% CI)

 − 40.8 (− 54.5, − 20.2)

 − 36.6 (− 50.2, − 16.5)

 P value

0.001

0.002

DSS, LS mean

2.12

3.06

2.12

2.89

 n

99

125

99

125

 Difference vs placebo (95% CI)

 − 0.94 (− 1.65, − 0.22)

 − 0.77 (− 1.43, − 0.11)

 Reduction vs placebo, % (95% CI)

 − 30.6 (− 45.2, − 7.7)

 − 26.6 (− 41.6, − 3.9)

 P value

0.010

0.022

DMS, LS mean

0.20

0.86

0.24

0.84

 n

99

124

99

124

 Difference vs placebo (95% CI)

 − 0.66 (− 1.10, − 0.23)

 − 0.59 (− 0.95, − 0.24)

 Reduction vs placebo, % (95% CI)

 − 77.2 (− 97.5, − 44.2)

 − 70.8 (− 88.1, − 43.5)

 P value

0.003

0.001

  1. FAS full analysis set, LS least square, SLIT sublingual immunotherapy